Robert H I Andtbacka
Overview
Explore the profile of Robert H I Andtbacka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
4228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meric-Bernstam F, Sweis R, Hodi F, Messersmith W, Andtbacka R, Ingham M, et al.
Clin Cancer Res
. 2023 Jun;
29(12):2336.
PMID: 37309603
No abstract available.
2.
Andtbacka R, Wang Y, Pierce R, Campbell J, Yushak M, Milhem M, et al.
Cancer Res Commun
. 2023 Mar;
2(8):904-913.
PMID: 36923305
Purpose: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma...
3.
Curti B, Richards J, Hyngstrom J, Daniels G, Faries M, Feun L, et al.
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36564126
Background: Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell...
4.
Kwon O, Noh S, Park S, Andtbacka R, Hyngstrom J, Richardson R
J Physiol
. 2022 Nov;
601(3):451-467.
PMID: 36416565
The present study aimed to determine the isoform-specific role of the NADPH oxidases (NOX) in the endothelium-mediated vascular dysfunction associated with ageing. Endothelium-dependent [intraluminal flow- and acetylcholine (ACh)-induced] vasodilatation in...
5.
Meric-Bernstam F, Sweis R, Hodi F, Messersmith W, Andtbacka R, Ingham M, et al.
Clin Cancer Res
. 2021 Oct;
28(4):677-688.
PMID: 34716197
Purpose: This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of MIW815 (ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of IFN genes (STING) pathway, in...
6.
Yuan J, Khilnani A, Brody J, Andtbacka R, Hu-Lieskovan S, Luke J, et al.
Eur J Cancer
. 2021 Sep;
157:493-510.
PMID: 34561127
Immunotherapy has revolutionised cancer treatment through restoration of host antitumour immune response. Immune checkpoint inhibitors (ICIs) confer durable responses in only a subset of patients. Mechanisms of ICI resistance to...
7.
Andtbacka R, Curti B, Daniels G, Hallmeyer S, Whitman E, Lutzky J, et al.
J Clin Oncol
. 2021 Aug;
39(34):3829-3838.
PMID: 34464163
Purpose: We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. Patients And Methods: In this multicenter, open-label, phase II study,...
8.
Haymaker C, Johnson D, Murthy R, Bentebibel S, Uemura M, Hudgens C, et al.
Cancer Discov
. 2021 Mar;
11(8):1996-2013.
PMID: 33707233
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab...
9.
Vreeland T, Clifton G, Hale D, Chick R, Hickerson A, Cindass J, et al.
Ann Surg Oncol
. 2021 Feb;
28(11):6126-6137.
PMID: 33641012
Background: Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies. This novel vaccine strategy may prime a...
10.
Goldmacher G, Khilnani A, Andtbacka R, Luke J, Hodi F, Marabelle A, et al.
J Clin Oncol
. 2020 Jun;
38(23):2667-2676.
PMID: 32552274
No abstract available.